Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness
- PMID: 33609196
- PMCID: PMC9033715
- DOI: 10.1007/s10741-021-10080-2
Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness
Abstract
Amyloid transthyretin (ATTR) amyloidosis is a clinically heterogeneous and fatal disease that results from deposition of insoluble amyloid fibrils in various organs and tissues, causing progressive loss of function. The objective of this review is to increase awareness and diagnosis of ATTR amyloidosis by improving recognition of its overlapping conditions, misdiagnosis, and multiorgan presentation. Cardiac manifestations include heart failure, atrial fibrillation, intolerance to previously prescribed antihypertensives, sinus node dysfunction, and atrioventricular block, resulting in the need for permanent pacing. Neurologic manifestations include progressive sensorimotor neuropathy (e.g., pain, weakness) and autonomic dysfunction (e.g., erectile dysfunction, chronic diarrhea, orthostatic hypotension). Non-cardiac red flags often precede the diagnosis of ATTR amyloidosis and include musculoskeletal manifestations (e.g., carpal tunnel syndrome, lumbar spinal stenosis, spontaneous rupture of the distal tendon biceps, shoulder and knee surgery). Awareness and recognition of the constellation of symptoms, including cardiac, neurologic, and musculoskeletal manifestations, will help with early diagnosis of ATTR amyloidosis and faster access to therapies, thereby slowing the progression of this debilitating disease.
Keywords: ATTRv; Amyloidosis; Cardiomyopathy; Transthyretin amyloidosis; hATTR.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Conflict of interest statement
Jose N. Nativi-Nicolau reports funding for clinical trials from Pfizer, Akcea Therapeutics, and Eidos; educational grants from Pfizer; and consulting fees from Pfizer, Eidos, Akcea Therapeutics, and Alnylam. Chafic Karam reports consulting/educational activities for Akcea Therapeutics, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Medscape, and Sanofi Genzyme; and has received research grants from Sanofi Genzyme and Akcea Therapeutics. Sami Khella reports honoraria from Akcea Therapeutics and Alnylam. Mathew S. Maurer reports grants from Pfizer and Alnylam; and personal fees from Pfizer, Eidos, GlaxoSmithKline, Prothena, Akcea Therapeutics, and Ionis.
Figures
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
